Detalles de la búsqueda
1.
Inhibition of checkpoint kinase 1 following gemcitabine-mediated S phase arrest results in CDC7- and CDK2-dependent replication catastrophe.
J Biol Chem
; 294(6): 1763-1778, 2019 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30573684
2.
Reply to Koh: Signaling dynamics of DNA damage response invoked by combination therapy are dose-dependent.
J Biol Chem
; 294(6): 2192, 2019 02 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30737319
3.
Driving Diversity and Inclusion in Cancer Drug Development - Industry and Regulatory Perspectives, Current Practices, Opportunities, and Challenges.
Clin Cancer Res
; 29(18): 3566-3572, 2023 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37378578
4.
Electronic Nicotine Delivery Systems: An Updated Policy Statement From the American Association for Cancer Research and the American Society of Clinical Oncology.
J Clin Oncol
; 40(35): 4144-4155, 2022 12 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36287017
5.
Electronic Nicotine Delivery Systems: An Updated Policy Statement from the American Association for Cancer Research and the American Society of Clinical Oncology.
Clin Cancer Res
; 28(22): 4861-4870, 2022 11 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-36287033
6.
Comparison of the different mechanisms of cytotoxicity induced by checkpoint kinase I inhibitors when used as single agents or in combination with DNA damage.
Oncogene
; 39(7): 1389-1401, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31659257
7.
Differential Sensitivity to CDK2 Inhibition Discriminates the Molecular Mechanisms of CHK1 Inhibitors as Monotherapy or in Combination with the Topoisomerase I Inhibitor SN38.
ACS Pharmacol Transl Sci
; 2(3): 168-182, 2019 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32259055
Resultados
1 -
7
de 7
1
Próxima >
>>